|Year : 2021 | Volume
| Issue : 4 | Page : 316-325
Current perspectives in the treatment of childhood lichen planus
Sharad D Mutalik1, Vasudha A Belgaumkar2, Yashashree D Rasal1
1 Department of Dermatology, Maharashtra Medical Foundation's Joshi Hospital, Pune, Maharashtra, India
2 Department of Dermatology, BJ Government Medical College and Sassoon Hospital, Pune, Maharashtra, India
|Date of Submission||01-Nov-2020|
|Date of Decision||02-Mar-2021|
|Date of Acceptance||16-Apr-2021|
|Date of Web Publication||01-Oct-2021|
Sharad D Mutalik
Department of Dermatology, Maharashtra Medical Foundation's Joshi Hospital, 778, Deccan Gymkhana, Pune - 411 004, Maharashtra
Source of Support: None, Conflict of Interest: None
Childhood lichen planus (CLP) is relatively common in India. With a mean age of onset at 7–8 years, CLP poses a therapeutic challenge as most guidelines for treatment cater to adult lichen planus (LP) with no defined evidence-based recommendations for CLP. Each case of CLP needs customized therapy with a step-wise approach. Topical corticosteroids are ably supported by topical calcineurin inhibitors, while oral retinoids, immunosuppressants like cyclosporine, and immunomodulators such as dapsone and narrowband ultraviolet B phototherapy are taking center stage in place of oral corticosteroids as systemic treatment modalities. However, the management of mucosal and appendageal LP requires systemic steroids more often than not. For the present review, we extracted the available data published in the English literature (Google Scholar databases, PubMed, and Medline) using search terms “lichen planus,” “treatment,” “children,” “pediatric,” and synthesized documented evidence regarding the risk–benefit profile of each therapeutic modality used in CLP. Undoubtedly, reporting of anecdotal successes, case studies, and conducting randomized controlled trials will help to structure consensus guidelines for the therapeutic conundrum of CLP.
Keywords: Adolescent, children, lichen planus, pediatric, treatment
|How to cite this article:|
Mutalik SD, Belgaumkar VA, Rasal YD. Current perspectives in the treatment of childhood lichen planus. Indian J Paediatr Dermatol 2021;22:316-25
|How to cite this URL:|
Mutalik SD, Belgaumkar VA, Rasal YD. Current perspectives in the treatment of childhood lichen planus. Indian J Paediatr Dermatol [serial online] 2021 [cited 2021 Dec 5];22:316-25. Available from: https://www.ijpd.in/text.asp?2021/22/4/316/327447
| Introduction|| |
Lichen planus (LP) is a multifactorial, inflammatory disease of the skin, hair follicles, nails, and mucous membranes with diverse presentations and varying natural course. With an incidence of 2%–3% of total cases of LP, most childhood LP (CLP) cases are sporadic, with familial cases accounting for only 1%–2%., Children from the Indian subcontinent appear to have LP more frequently (prevalence up to 11%–19%), probably due to undefined genetic factors, environmental triggers, and possibly the Fitzpatrick skin type. The mean age of onset is 7.1–8.4 years with the earliest reported age at 2 weeks.
CLP is often asymptomatic yet deserves judicious treatment in view of probable chronicity and postinflammatory hyperpigmentation. Classical LP (42%–76%) is the most common morphology, followed by eruptive LP (13%), lichen planus hypertrophicus (LPH) (12%), and actinic LP (11.5%). The Koebner's phenomenon occurs more frequently in children (24%–28%); however, both scalp (0%–9%) and nail involvement (8.7%) are uncommon., Nail LP in childhood presents mostly as longitudinal ridging, with twenty-nail dystrophy and idiopathic atrophy being peculiar presentations. The mucous membrane involvement in CLP is largely asymptomatic with significantly lower prevalence (0.03%) and better prognosis as compared to adults.,
Management of CLP begins with a search for the causative trigger including history about familial LP (autosomal dominant with variable penetrance) which presents with earlier onset, and/or recalcitrant course, auto-immune diseases (such as systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis, vitiligo, and alopecia areata), and immunization (uncommonly after hepatitis B, influenza, and herpes zoster vaccine). The association of LP with hepatitis C virus infections has not been noted in children, but the association with human herpes virus-7 infections has been documented., While antihypertensives (captopril, enalapril, labetalol, and propranolol), diuretics (hydrochlorothiazide), antimalarials (hydroxychloroquine and quinidine), penicillamine, and gold salts are known to trigger LP, drugs frequently used in children and adolescents such as griseofulvin, tetracycline, carbamazepine, phenytoin, and nonsteroidal anti-inflammatory medications have also been occasionally implicated. Attention also needs to be paid to the presence of mercury compounds in dental amalgam or gold dental restorations which have been causally related to mucosal LP.
Overall, CLP has a favorable response to treatment with two-third of cases showing resolution within 1 year. About 10%–20% of cases show intermittent recurrences for years with disfiguring residual pigmentation. Malignant transformation in pediatric oral LP, though rarely reported (0.4%–12.5% in adults), is a possibility, particularly in erosive and atrophic types, owing to the longer duration of lesions and high renewal rate of oral epithelial cells in children. Therefore, regular meticulous follow-up is warranted.,
| Treatment of Childhood Lichen Planus|| |
Related English literature published until June 2021 was obtained from the following electronic database searches: Google Scholar, Medline, and PubMed. The following search terms were transcribed to yield articles of relevance: “lichen planus,” “treatment,” “children,” and “pediatric” in combination with “cutaneous,” “mucosal,” “appendageal,” and “nail.” Screening of the literature (25 articles from Google Scholar, 10 each from Pubmed and Medline) was performed independently by all the authors to validate the reliability of the information and obviate author bias. Reference lists of included papers were scanned, and further relevant publications were retrieved and categorized as case reports, case series, and review articles. We were unable to retrieve any randomized case–control trials specific for CLP. The documented evidence was synthesized to summarize and highlight the risk–benefit profile of each therapeutic modality for specific presentations of CLP.
The literature about CLP and its treatment is chiefly anecdotal with most of the data drawn from adult nonprospective observational randomized trials or recommendations based on the personal experience of experts. The reasonable approach in the management of CLP remains removal of triggers (where identified) with control of the severity of lesions, suppression of the pruritus, and curtailing the cosmetically debilitating postinflammatory hyperpigmentation.
| Topical Therapies in Pediatric Cutaneous Lichen Planus|| |
Emollients and antipruritic agents
Water-based moisturizers provide a cooling effect from water evaporation on the skin surface providing antipruritic effect and minimizing koebnerization. Antipruritic lotions containing menthol, camphor, and calamine are particularly beneficial in patients with infrequent but violent paroxysm of pruritus. In addition, harsh soaps are best avoided and children are advised to wear full sleeve cotton clothes, shoes, and socks (instead of playing barefoot) which can help reduce friction-related Koebner phenomenon.
| Topical Glucocorticosteroids|| |
Class II–IV topical glucocorticosteroids (TCs) in a cream base with or without occlusion applied carefully and sparingly as a very thin film once daily has been used for the treatment of localized classic cutaneous CLP. The pruritus usually reduces by 3–4 weeks, while flattening of lesions is achieved at around 6 weeks. Most cases of localized cutaneous LP show remission by the 20–24th week of therapy., However, TCs do little to change the chronic course of disease and cannot prevent emergence of new lesions or hasten the resolution of the postinflammatory hyperpigmentation. Once the lesions have changed color from erythematous–violaceous to gray-brown with flattening, there is no further response to the TCs. TCs are quite safe only if used for few weeks, not more than 2–4 months, to avoid local side effects.
The use of Class I super-potent TCs in ointment base under hydrocolloid occlusive dressing is reserved with caution for localized discrete hypertrophic, erosive, and palmoplantar LP., It has to be borne in mind that employing occlusion has a very real risk of accelerated local toxicity and percutaneous absorption (e.g., tachyphylaxis, suppression of hypothalamic-pituitary-adrenal axis, Cushing's syndrome, and growth retardation) and is not routinely recommended in children.
Intra- and sublesional injections with triamcinolone acetonide (TAC) in strength of 5–20 mg/ml injected in the center of lesion (0.5–1 ml per 2-cm2 lesion) is an effective therapy for recalcitrant thicker lesions of LPH, palmoplantar LP, and other unresponsive lesions is an effective therapy for recalcitrant thicker lesions of LPH, palmoplantar LP, and other unresponsive lesions. Given once in 3–6 weeks, they provide immediate short-term benefits with symptomatic relief within 72 hours.
| Topical Calcineurin Inhibitors|| |
Topical calcineurin inhibitors (TCIs) like tacrolimus 0.03% ointment and pimecrolimus 1% cream are valid alternatives to TCs and are of undeniable value in maintaining remission. Topical tacrolimus has been found to be most effective in scaly papuloplaque lesions. There are no documented reports of use of 0.1% tacrolimus for CLP. Pimecrolimus has been used in generalized and palmoplantar LP. Barring LPH, they are good step-down agents or steroid-sparing adjuncts, particularly in children with steroid-induced side effects. Due to the potential risk of malignancies, they are not recommended below 2 years of age.,, Usually, TCIs are safe and well tolerated. The most common side effects are burning sensation, transient pruritus, and erythema at the site of the application which can be reduced by pre refrigerating the medication.
Topical tazarotene with keratolytic agents (6%–12% salicylic acid) is of value in the treatment of palmoplantar LP. Topical calcipotriol has limited benefit and is not used routinely.
[Table 1] details studies documenting topical therapies for LP.,,
|Table 1: Studies depicting use of topical therapeutics in childhood lichen planus|
Click here to view
| Systemic Therapies in Pediatric Cutaneous Lichen Planus|| |
First-generation H (1) antihistamines at bedtime are vital in controlling pruritus with a desirable sedative effect. However, they may cause disruption of sleep patterns and affect learning when taken for a prolonged duration. Nonsedative second-generation H (1) antihistamines are useful for daytime control of pruritus. They are well tolerated with fewer adverse effects on cognition in children.
| Systemic Glucocorticosteroids|| |
Glucocorticoids (GC) are widely used for CLP as they score well in view of efficacy, availability, and cost. Their drawback includes the systemic side effects and the risk of relapse when doses are tapered.
| Oral Glucocorticosteroids|| |
A short course of systemic GC over 2–3 weeks with gradual tapering over 4–6 weeks is justified as first-line therapy in very early presentation of classic eruptive LP, severe extensive recalcitrant LP, severe LPH, eczematized, atrophic, or bullous LP.,, LP pemphigoides (LPP) and bullous LP require high doses of systemic steroids along with dapsone or azathioprine.
Widespread cutaneous lesions respond well to short-course therapy with systemic steroids but tend to relapse as the dose is reduced. Prednisolone at a dose of 0.5–2 mg/kg/day is tapered slowly at the rate of 2.5 mg/week over 2–6 weeks to minimize the occurrence of relapse.
Oral GC needs to be administered only as short courses in children. Long courses, especially during two major growth spurts of childhood: before age 2 and at puberty, may cause loss of height. Betamethasone in an early morning dose of 0.1 mg/kg dose on 2 consecutive days per week over 3 months as oral mini-pulse therapy has been used in CLP with good response and minimal adverse effects.
Intramuscular (i/m) injections of TAC, 10–20 mg every 6–8 weeks for a maximum of 3 doses, can be used in unresponsive cases of generalized cutaneous CLP although there is no corroborative published evidence. Hypothalamo-pituitary-adrenal suppression and myopathy due to longer-acting TAC entail cautious use restricted to children >6 years of age.,
| Retinoids|| |
The anti-inflammatory retinoids have shown a good level of evidence of efficacy for cutaneous LP. Acitretin (<0.5–1 mg/kg/day) is safe, effective, well tolerated in children with LPH and acute severe generalized or exanthematous mucocutaneous LP. Due to a longer half-life, it induces sustained remission. For dose titration according to weight, the capsule contents can be opened and dissolved in a liquid dietary medium or frozen and cut in the required fraction and dispensed in a liquid, namely honey, milk, or infant formula before administration. Since acitretin is sensitive to light, the remaining fraction should be discarded.
A therapy of 8 weeks is usually sufficient. It can be safely combined with topical drugs and narrowband ultraviolet B (NBUVB) phototherapy. However, the duration of post-treatment remission in children remains undocumented.,
Long-term use of high-dose acitretin (generally not required for CLP) may be associated with premature closure of the epiphyses. Cheilitis, xerosis, pruritus, epistaxis, and transient elevation in serum lipids and hepatic enzymes can be managed symptomatically and do not warrant discontinuation. Oral isotretinoin (0.5 mg/kg/day) too has been found to be useful in severe cases of mucocutaneous LP.
| Oral Immunosuppressants|| |
There are no specific guidelines or consensus yet on cyclosporine (CsA) use in pediatric dermatosis, and all the data available are experience-based retrospective analysis, mostly in cases of atopic dermatitis and psoriasis. Anecdotal reports in adults suggest efficacy in severe disseminated treatment-resistant CLP. It has a rapid onset of action and provides long-term remission in cutaneous CLP.
In children, the oral absorption may be lower, the clearance more rapid, and the volume distribution greater at a steady state, necessitating somewhat higher dosages and more frequent administration than adults. Both low (1–2 mg/kg) and high doses (3–6 mg/kg) have been found to offer control or cure lesions by 6 weeks, with relapses controlled with topical steroids. Pruritus disappears by 1–2 weeks of treatment with sustained remission for up to 10 months. Phototherapy is contraindicated with this regimen as there is a high risk of epithelial skin cancer.
Availability as an oral solution (100 mg/ml, 50 ml) allows accurate weight-based dose titration with the help of a calibrated syringe. Administered in milk or orange juice (not grapefruit juice) to conceal the taste, it should preferably be given in glass or ceramic cups since CsA binds to plastics. Although fairly well tolerated, regular serum creatinine and blood pressure monitoring is recommended and it is prudent to keep daily doses <5 mg/kg to avoid renal toxicity.,, Used judiciously, CsA is a safe and effective option for extensive CLP, particularly as a fast-acting rescue drug offering longer periods of remissions.
| Methotrexate|| |
Methotrexate (MTX) with folic acid co-administration is safe and effective in CLP in doses as low as 0.2–0.5 mg/kg/week with a reduction in pruritus by 4 weeks and response by 14–24 weeks. This dosing can be used for short periods in acute generalized recalcitrant or severe mucocutaneous CLP including LPP.,
MTX offers the advantage of convenient weekly oral or subcutaneous doses. Orally, it can be given as crushed tablets mixed in nonmilk food as milk may interfere with absorption. Nausea and vomiting are commonly reported adverse effects with transient elevation in liver enzymes. In acute LP after achieving therapeutic control, it is recommended to taper the dose to reduce side effects. In cases where LP has been chronic or recurrent, MTX is not the preferred therapy.
Mycophenolate mofetil and Azathioprine
There are no documented reports of the use of mycophenolate mofetil (MMF) or azathioprine (AZA) in CLP.
MMF should be reserved for severe, recalcitrant, erosive mucocutaneous LP in a dose range of 600 mg/m2 daily, for children above 6 months., Complete blood counts are to be monitored weekly during the 1st month of therapy, followed by, twice monthly for 2 months, and then monthly for the remainder of therapy. Side effects include mild gastrointestinal symptoms and cytopenia.
AZA is reserved for children with recalcitrant LP or as steroid-sparing agents in LPP. The concern of immunosuppression and the potential development of malignancy has limited its use. AZA has a slow onset of action. Pediatric patients with normal thiopurine methyltransferase (TPMT) activity levels (≥15.4 U/mL) should receive AZA at 2.5 mg/kg/day, possible carriers of a mutant allele (11.9-15.3 U/mL) 2.0 or 2.5 mg/kg/day, while definite carriers with intermediate enzyme levels (6.0–11.8 U/mL) begin at 1.0 mg/kg/day. Individuals with low TPMT levels (≤5.9 U/mL) should not be prescribed AZA.,
Guidelines for vaccination in children on immunosuppressants
Immunization of the child should preferably be updated for age before commencing immunosuppressive therapy. Systemic steroid dose higher than prednisolone 2 mg/kg, (or 20 mg/day or its equivalent for those weighing more than 10 kg) for a period longer than 14 days causes immunosuppression. Live vaccines should not be administered to these children until at least 1 month after steroid discontinuation. Live vaccinations are not contraindications with lower doses or shorter duration of oral treatment or with topical or intralesional steroid therapy.
Live vaccines should be avoided for at least 3 months after other immunosuppressive drugs (CsA, MTX, AZA, and MMF) and 6 months after biologic agents.
Killed vaccines are safe but may be less efficacious. There are no specific recommendations about when to restart immunosuppressives after vaccination. However, immunosuppressive therapy initiation should be deferred for 4 weeks after live vaccine and 2 weeks after inactivated vaccines.
| Oral Immunomodulators|| |
Dapsone is an effective, safe therapy with a remarkable antipruritic effect. Used for acute generalized LP, it reduces itching within 2–4 weeks with flattening of lesions in 8–10 weeks with complete remission achieved in 14–16 weeks. Localized LP may take longer to respond, usually up to 20–22 weeks. It has been found to be ineffective in LPH. It has value as a steroid-sparing agent in the management of LPP.
However, dapsone (1.5–2 mg/kg/day as a single bedtime dose) can be given only when the hemoglobin is >10 gm% with age-appropriate G6PD levels, with monthly monitoring of hemogram and liver function tests.
Metronidazole has been used at a dose of 10 mg/kg dose, three times a day leading to a reduction in pruritus within 3–6 weeks in cases of acute generalized, classic CLP and LPH. Complete remission has been achieved by 20 weeks.,
Narrow-band ultraviolet B phototherapy (NB-UVB) is safe and effective, particularly in acute eruptive or generalized LP or as maintenance therapy while tapering systemic drugs. Given thrice a week on nonconsecutive days (average 40–50 sittings, at a starting UVB dose of 150 mJ/cm2, with weekly increments of 20%, according to the clinical response and tolerance), it leads to control of pruritus and complete flattening of lesions. Oral photochemotherapy with psoralens and ultraviolet A is contraindicated in children aged below 11 years because of psoralen toxicity (e.g. gastric and ocular damage).
Hydroxychloroquine (4–6 mg/kg/day as a short tapered course over 6–8 weeks) has promising efficacy in actinic LP due to its immunomodulatory, anti-inflammatory, and photoprotective effect. Adverse effects include gastrointestinal disturbance and headache.
It is postulated that apremilast could be effective in the treatment of lichenoid dermatitis; however safety, efficacy, and posology in children remain to be evaluated. A study in pediatric patients with psoriasis reports the use of 20–30 mg apremilast in ages 12–17 with weight >35 kg and 20 mg in ages 6–11 years with weight >15 kg.,
Oral erythromycin (30 mg/kg in four divided doses) and nicotinamide (150 mg three times a day) have been shown to be useful in LPP or bullous LP.,
Biologics (like adalimumab) and Janus kinase inhibitors (tofacitinib) have been used in therapy of LP in adults; however, there is no evidence of their use in pediatric subjects., Other drugs such as griseofulvin, pulsed itraconazole, and subcutaneous enoxaparin have been tried with variable success.,
[Table 2] enumerates studies reporting systemic therapies in CLP. [Table 3], [Table 4], [Table 5] summarize therapeutic options for the management of cutaneous CLP.,,,,
|Table 2: Studies documenting systemic therapies for childhood lichen planus|
Click here to view
|Table 3: Interventions (as monotherapy or in combination) suggested for localized pediatric cutaneous lichen planus|
Click here to view
|Table 4: Interventions suggested for acute eruptive generalized pediatric cutaneous lichen planus (in addition to topical therapy as detailed in Table 3)|
Click here to view
|Table 5: Interventions for generalized chronic/recurrent pediatric cutaneous Lichen planus (in addition to topicaltherapy detailed in Table 3)|
Click here to view
| Treatment of Pediatric Mucosal Lichen Planus|| |
Pediatric oral lichen planus
Majority of cases tend to be asymptomatic and can be left untreated with careful semiannual follow-up; however, erosive or ulcerated oral lichen planus (OLP) often has a refractory course and demands quick symptomatic therapy ensuring compliance and palliation., Reduced intake of spicy, acidic food with avoidance of oral hygiene products like minty toothpastes and trauma (lip/cheek chewing) are to be advised. Local anesthetic sprays or soothing gels containing aloe barbadensis during meal times offer symptomatic relief.
The first-line therapy is high-potency topical corticosteroids in orabase applied as a thin film on dried oral mucosa twice a day with the child refraining from eating, drinking, or speaking for 30 min post application. It is then tapered as required over several months. Prolonged use may cause secondary candidiasis, a smarting sensation in the mouth, gingival tenderness, adrenal insufficiency, and potential tachyphylaxis. Concomitant antimycotic treatment along with alcohol-free oral rinse with plaque control regimen is advised.
Intra- and sublesional injections in fractional amounts circumferentially just below the edge of ulcers at various points with TAC (0.5 ml of 10 mg/ml to avoid mucosal atrophy) repeated at an interval of 3–6 weeks are used with rapid relief of pain and ulceration at the end of 2 weeks. Additional injections are given in the floor in case of large ulcers. Lip lesions tend to respond less favorably. In severe cases, 0.3–0.5 mg/kg of oral steroid with tapering over 3–6 weeks is helpful.,
In children between 2 and 15 years, tacrolimus 0.03% ointment is used. A common side effect is local burning which improves with time or can be minimized by refrigerating the ointment prior to application. Comparatively pimecrolimus 1% cream causes less local burning and effectively treats erosive OLP with long-lasting therapeutic effects. They are to be applied twice a day for 4–6 weeks.
Topical isotretinoin gel 0.1% for buccal mucosal lesions was found to be effective in providing symptomatic relief as well as achieving early response (within 6 weeks). Topical tretinoin 0.05% gel used twice a day for 2 weeks has resulted in remission by 4 weeks. Recombinant bovine basic fibroblast growth factor gel, a pleiotropic cytokine that promotes angiogenesis, neurotrophy, and mucosal integrity, has been reported to induce remission in childhood OLP by 2 months.
In diffuse/multisite recalcitrant erosive OLP, systemic steroids can be given either in intermediate doses (0.3–0.5 mg/kg) as short bursts to induce remission or as a mini-pulse with betamethasone on 2 consecutive days a week.
Oral acitretin (0.5–1 mg/kg) provides satisfactory response at 8–12 weeks with longer remissions. Oral immunosuppressants, particularly CsA, can be considered in severe OLP recalcitrant to first-line therapies (others being MTX, MMF, and AZA). Apremilast, griseofulvin, dapsone, hydroxychloroquine, zinc supplementation, curcuminoids, NBUVB phototherapy, cryotherapy, and interferons among others have been used on a very limited basis with varied success. Lasers (Excimer, diode, CO2) give gratifying results in OLP and have shown to yield long-term remission of symptoms, and may be promising as first-line therapy in painful OLP.,, Excision with free tissue grafts is alternative in localized lesions of erosive LP.
| Pediatric Genital Lichen Planus|| |
Few studies have reported genital involvement in children. It should however be actively looked for, in patients with oral LP, where the lesions may go unnoticed by the patient.
Plain warm water washes, avoidance of soap and tight underwear, with the application of liberal nonirritating emollient like petrolatum or chilled aqueous cream pre and post micturition with icepacks are important supportive measures. Mid to ultrapotent corticosteroids in ointment base are applied once a day as a thin smear in mild cases till relief is obtained, followed by slow tapering. The cream may be preferred but is more likely to sting on application. Hydrocortisone foam can be used inside the vagina or anus. TCI once or twice daily have been used in erosive disease with limited success. High-dose systemic corticosteroids in combination with steroid-sparing agents have been used, with steroids tapered over 3–6 weeks after the effect of steroid-sparing agent sets in. In severe refractory cases, stronger immunesuppressants may be needed such as MTX, CsA, MMF, or AZA. Surgical release of LP-induced vulval and vaginal adhesions and scarring may occasionally be performed to reduce urination difficulties.
Pediatric appendageal lichen planus
Lichen planopilaris is a rare, recalcitrant form of cicatricial alopecia occasionally reported in children. First-line therapy for scalp involvement (<10% without cosmetically disfiguring alopecia) is ultra-potent topical corticosteroids or intralesional corticosteroids (ILS) in a tapering regimen. High-potency topical steroids are used twice daily for the initial 1 month and tapered to once daily for the subsequent 3 months and finally on alternate days for 3 months thereafter. ILS (TAC 3–5 mg/ml 3–4 weekly) is given circumferentially along the active edge of alopecic patch. TCIs (tacrolimus 0.03% ointment) are advised twice a day for at least 1 month. Oral corticosteroids are beneficial in rapidly progressive scarring disease (1 mg/kg tapered over 3–4 months). Retinoids are used as second-line therapy in extensive lesions. Acitretin (0.5–0.7 mg/kg) or isotretinoin (0.3–0.5 mg/kg) is used especially in cases with pronounced perifollicular hyperkeratosis. Oral immunosuppressants like MTX are an effective long-term alternative after initial corticosteroid therapy. CsA is used in refractory lichen planopilaris (3–5 mg/day for 3–5 months).,,
Pediatric nail lichen planus
In most cases, nail LP (NLP) in children affects the nail matrix which if left untreated may lead to scarring. Systemic corticosteroids halt the disease process and preserve the existing nail. They may be administered orally (prednisolone, 0.5–0.75 mg/kg/day over 1–12 weeks/oral mini-pulse with dexamethasone 2.5 mg/day on 2 consecutive days a week) or as intramuscular injection (TAC 0.5–1 mg/kg every 30 days). Intramuscular TAC has been reported to give a complete cure of fingernails at 6–8 months and toenails at 8–12 months while decreasing the risk for systemic side effects in comparison with oral corticosteroids. Adverse effects included lipoatrophy at the injection site and cushingoid facies. Relapses might occur with both oral and intramuscular corticosteroids; however, these recurrences are always responsive to therapy.
NLP presenting as twenty-nail dystrophy often improves without any treatment. Treatment is prescribed for cosmetic reasons with bland emollients and camouflage with nail polish. Nail plate dressings (ultra-thin adhesive bandage applied once a week with lactic acid, silicon dioxide, aluminum acetylacetonate, copolymer of vinyl acetate with acrylic acid, and azelaic acid) were found to improve symptoms after 3 months in a pediatric patient. Topical therapy includes corticosteroids, calcipotriol/betamethasone dipropionate ointment, tazarotene gel (0.05%), and 5% 5-fluorouracil application on periungual folds. Acitretin has been used in doses of 0.3–0.5 mg/kg/day in the treatment of trachyonychia secondary to LP. Other systemic treatments include biotin 2.5 mg/day, CsA 2–3.5 mg/kg/day, systemic corticosteroids, and tofacitinib citrate.
The scarring atrophic variant of NLP is found frequently in Indian children. Oral prednisolone as a tapering dose over 4–12 weeks may be tried to halt the acute and rapid course that may lead to diffuse painless nail destruction in a few months. Permanent damage to the nail matrix needs surgical correction after subsidence of disease activity and cessation of all oral medication.,
[Table 6] summarizes published case series documenting therapeutic options for CLP.,
|Table 6: Case series illustrating treatment modalities of pediatric lichen planus|
Click here to view
| Conclusion|| |
Most children with LP respond to treatment with full clearance over 1–6 months. Robust evidence of efficacy is lacking for most therapeutics and a more lucid consensus for the treatment of CLP is the need of the hour.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Paller AS, Mancini AJ. Papulosquamous and related disorders. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence. 5th
ed. Canada: Elsevier; 2016. p. 73-94.
Malathi M, Thappa DM. Management of childhood lichen planus. NJDVL 2014;12:1-6.
Ravikiran SP, Jaiswal AK, Anupama YG. Lichen planus in children: A retrospective study in 76 patients at a tertiary care center in South India. Indian J Paediatr Dermatol 2017;18:209-13. [Full text]
Kanwar AJ, De D. Lichen planus in children. Indian J Dermatol Venereol Leprol 2010;76:366-72.
] [Full text]
Tosti A, Piraccini BM, Cambiaghi S, Jorizzo M. Nail lichen planus in children: Clinical features, response to treatment, and long-term follow-up. Arch Dermatol 2001;137:1027-32.
Sharma G, Sardana D, Vohra P, Rehani S, Nagpal A. Lichen planus in a pediatric patient: A novel sharma therapeutic approach. J Dent (Tehran) 2017;14:109-14.
Wang F, Tan YQ, Zhang J, Zhou G. Familial oral lichen planus in a 3-year-old boy: A case report with eight years of follow-up. BMC Oral Health 2020;20:341.
Loannides D, Vakirlis E, Kemeny L, Marinovic B, Massone C, Murphy R, et al.
European S1 guidelines on the management of lichen planus: A cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 2020;34:1403-14.
Purnamawati S, Indrastuti N, Danarti R, Saefudin T. The role of moisturizers in addressing various kinds of dermatitis: A review. Clin Med Res 2017;15:75-87.
Saraswat A. Local therapy of Lichen planus. In: Khopkar U, Valia A.eds. Lichen planus.1st ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013. p.204-9.
Nischal U, Kharkar V. Different treatment modalities in the treatment of childhood lichen planus. Indian J Drugs Dermatol 2016;2:87-92. [Full text]
Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998;134:1521-30.
Fortina AB, Giulioni E, Tonin E. Topical tacrolimus in the treatment of lichen planus in a child. Pediatr Dermatol 2008;25:570-1.
.Lee YK, Ku BS, Kim YH. A case of generalized lichen planus treated with topical pimecrolimus. Korean J Dermatol 2007;45:397-400.
Jue MS, Lee JW, Ko JY, Yeo KY, Kim JS, Yu HJ. Childhood lichen planus with palmoplantar involvement. Ann Dermatol 2010;22:51-3.
Gutte R, Khopkar U. Palmoplantar Lichen planus. In: Khopkar U, Valia A, editors. Lichen Planus. 1st
ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013. p. 74-83.
Bayramgürler D, Apaydin R, Bilen N. Limited benefit of topical calcipotriol in lichen planus treatment: A preliminary study. J Dermatolog Treat 2002;13:129-32.
Nanda A, Al-Ajmi HS, Al-Sabah H, Al-Hasawi F, Alsaleh QA. Childhood lichen planus: A report of 23 cases. Pediatr Dermatol 2001;18:1-4.
Kanwar AJ, De D. Lichen planus in childhood: Report of 100 cases. Clin Exp Dermatol 2010;35:257-62.
Sharma G, Sardana D, Vohra P, Rehani S, Nagpal A. Oral lichen planus in a pediatric patient: A novel therapeutic approach. J Dent (Tehran) 2017;14:109-14.
Fitzsimons R, van der Poel LA, Thornhill W, du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child Educ Pract Ed 2015;100:122-31.
Lehman JS, Tollefson MM, Gibson LE. Lichen planus. Int J Dermatol 2009;48:682-94.
Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al
. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.
Verma KK, Mittal R, Manchanda Y. Lichen planus treated with betamethasone oral mini-pulse therapy. Indian J Dermatol Venereol Leprol 2000;66:34-5.
] [Full text]
Gautam M, Tahiliani H, Nadkarni N, Patil S, Godse K. Acitretin in pediatric dermatoses. Indian J Paediatr Dermatol 2016:17:87-94.
Brockow K, Abeck D, Haupt G, Ring J. Exanthematous lichen planus in a child – Response to acitretin. Br J Dermatol 1997;136:287-9.
Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, et al.
Systemic treatment of pediatric psoriasis: A review. Dermatol Ther (Heidelb) 2016;6:125-42.
Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis 1985;35:385-6, 390-1, 393.
Patro N, Panda M, Dash M. Cyclosporine in recalcitrant pediatric dermatoses – A retrospective analysis of thirty children. Indian J Paediatr Dermatol 2020;21:98-104. [Full text]
Manousaridis I, Manousaridis K, Peitsch WK, Schneider SW. Individualizing treatment and choice of medication in lichen planus: A step by step approach. J Dtsch Dermatol Ges 2013;11:981-91.
Gautam M, Nadkarni N, Patil S. Review of systemic methotrexate therapy on pediatric dermatoses. Indian J Paediatr Dermatol 2014;15:66-73. [Full text]
Kanwar AJ, De D. Methotrexate for treatment of lichen planus: Old drug, new indication. J Eur Acad Dermatol Venereol 2013;27:e410-3.
Pinkerton CR, Welshman SG, Glasgow JF, Bridges JM. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet 1980;2:944-6.
Park H. The emergence of mycophenolate mofetil in dermatology: From its roots in the world of organ transplantation to its versatile role in the dermatology treatment room. J Clin Aesthet Dermatol 2011;4:18-27.
Downing HJ, Pirmohamed M, Beresford MW. Pediatric use of mycophenolate mofetil. Br J Clin Pharmacol 2012;75:45-59.
Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: Clinical response and thiopurine monitoring. J Am Acad Dermatol 2013;68:29-35.
Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI, et al.
Off-label use of azathioprine in dermatology: A systematic review. Arch Dermatol 2011;147:474-88.
Moore DL. Immunization of the immunocompromised child: Key principles. Paediatr Child Health 2018;23:203-5.
Arumilli KP, Gandikota RR, Arumilli PC. Evaluation of narrowband ultraviolet B phototherapy in patients with generalized lichen planus. J NTR Univ Health Sci 2018;7:157-61. [Full text]
Ramírez P, Feito M, Sendagorta E, González-Beato M, De Lucas R. Childhood actinic lichen planus: Successful treatment with antimalarials. Australas J Dermatol 2012;53:e10-3.
Paul J, Foss CE, Hirano SA, Cunningham TD, Pariser DM. An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series. J Am Acad Dermatol 2013;68:255-61.
Paller AS, Hong Y, Becker EM, de Lucas R, Paris M, Zhang W, et al.
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. J Am Acad Dermatol 2020;82:389-97.
Cohen DM, Ben-Amitai D, Feinmesser M, Zvulunov A. Childhood lichen planus pemphigoides: A case report and review of the literature. Pediatr Dermatol 2009;26:569-74.
Gautam M, Shukla R. Biologics in pediatric dermatology. Indian J Paediatr Dermatol 2021;22:107-17. [Full text]
Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. J Allergy Clin Immunol 2020;145:1708-10.e2.
Yasar S, Serdar ZA, Goktay F, Doner N, Tanzer C, Akkaya D, et al.
The successful treatment of palmoplantar hyperkeratotic lichen planus with enoxaparin. Indian J Dermatol Venereol Leprol 2011;77:64-6.
] [Full text]
Kumar V, Garg BR, Baruah MC, Vasireddi SS. Childhood lichen planus (LP). J Dermatol 1993;20:175-7.
Handa S, Sahoo B. Childhood lichen planus: A study of 87 cases. Int J Dermatol 2002;41:423-7.
Kwee DJ, Dufresne RG, Ellis DL. Childhood bullous lichen planus. Pediatr Dermatol 1987;4:325-7.
Cox T, Woodhead J, Nelson BL. Reticular oral lichen planus. Head Neck Pathol. 2020;14:192-4.
Mansourian A, Momen-Heravi F, Saheb-Jamee M, Esfehani M, Khalilzadeh O, Momen-Beitollahi J. Comparision of aloe vera mouthwash with triamcinolone acetonide 0.1% on oral lichen planus: A randomized double-blinded clinical trial. Am J Med Sci 2011;342:447-51.
Narges G, Maryam-Sadat SA, Nafiseh S. Intralesional corticosteroid injection as an effective treatment method for oral lesions: A meta-analysis. Braz J Pharm Sci 2020;56:e18077.
Samycia M, Lin An efficacy of topical calcineurin inhibitors in lichen planus. J Cutan Med Surg 2012;16:221-9.
Petruzzi M, Lucchese A, Lajolo C, Campus G, Lauritano D, Serpico R. Topical retinoids in oral lichen planus treatment: An overview. Dermatology 2013;226:61-7.
Deshpande A. Successful use of oral acetretin in oral lichen planus. Indian J Drugs Dermatol 2017;3:24-7. [Full text]
Derikvand N, Ghasemi SS, Moharami M, Shafiei E, Chiniforush N. Management of oral lichen planus by 980 nm diode laser. J Lasers Med Sci 2017;8:150-4.
Prasanthi G, Anandan S. Oral Lichen planus. In: Khopkar U, Valia A, editors. Lichen Planus. 1st
ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013. p. 97-115.
Kolalapudi SA, Saka S, Konala S. Lichen planus in children: A prospective study over a period of 2.5 years. J NTR Univ Sci 2020;9:161-3.
Khurana A, Tandon S, Marfatia YS, Madnani N. Genital lichen planus: An underrecognized entity. Indian J Sex Transm Dis AIDS 2019;40:105-12.
Christensen KN, Lehman JS, Tollefson MM. Pediatric lichen planopilaris: Clinicopathologic study of four new cases and a review of the literature. Pediatr Dermatol 2015;32:621-7.
Chieregato C, Zini A, Barba A, Magnanini M, Rosina P. Lichen planopilaris: Report of 30 cases and review of the literature. Int J Dermatol 2003;42:342-5.
Haldar SS, Khopkar U. Nail lichen planus. In: Khopkar U, Valia A, editors. Lichen Planus. 1st
ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013. p. 84-96.
Kolbach-Rengito M, Navajas-Galimany L, Araneda-Castiglioni D. Efficacy of acetretin and topical clobetasol in trachyonychia involving all twenty nails. Indian J Dermatol Venereol Leprol 2016;82:732-4.
Jacobsen AA, Tosti A. Trachyonychia and twenty-nail dystrophy: A comprehensive review and discussion of diagnostic accuracy. Skin Appendage Disord 2016;2:7-13.
Kumar B, Kaur I, Bhattacharya M. Dapsone in lichen planus. Acta Derm Venereol 1994;74:334.
Pandhi D, Singal A, Bhattacharya SN. Lichen planus in childhood: A series of 316 patients. Pediatr Dermatol 2014;31:59-67.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]